article thumbnail

Preserving Patient Access to Compounded Medications Act of 2017

Pharmacy Times

The act would have permitted health care facilities to stock up on compounded medications without forcing the supplying 503A pharmacies to register as outsourcing facilities.

article thumbnail

GSK partners LifeMine on fungi-derived medicines

pharmaphorum

GlaxoSmithKline has thrown its financial and drug development weight behind LifeMine Therapeutics, a US startup that aims to find new therapeutics from fungi – widely regarded as an underexplored resource of biologically-active compounds. Greg Verdine – LifeMine.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The digital transformation of pharma’s physician engagement strategies

pharmaphorum

In doing so it’s compounded pre-existing pressure with pharma, where schedules are shrinking and policies are often already restrictive enough to build barriers for effective physician engagement. The threat of disease spread and other risk factors from COVID-19 have only compounded this.

article thumbnail

Key vaccine adjuvant biosynthesised

European Pharmaceutical Review

highlighted in the paper a key milestone achieved by the vaccine industry in 2017: “the first saponin adjuvant AS01 was approved for use in a human vaccine, the highly effective shingles vaccine Shingrix (produced by GSK).” “Our Martin et al. Our study opens unprecedented opportunities for bioengineering vaccine adjuvants.

article thumbnail

Rapid microbiology testing market growth expected 2022 to 2027

European Pharmaceutical Review

A report has predicted the rapid microbiology testing market size is estimated to grow at a compound annual growth rate (CAGR) of 9.31 The research includes historic market data from 2017 to 2021, using 2022 as the base year. million in 2017 and continued to grow until 2021. percent between 2022 and 2027.

article thumbnail

Dr Reddy’s jumps on medical cannabis train, buying Nimbus Health

pharmaphorum

Legislation is already in place allowing companies to grow the plant for medicinal purposes under license, doctors have been able to prescribe it since 2017 with full reimbursement from health insurers.

article thumbnail

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

pharmaphorum

Radioligand therapy combines a targeting compound that binds to markers expressed by tumours with a radioactive isotope. billion acquisition of France’s Advanced Accelerator Applications (AAA) in 2017. The latter inhibits tumour growth and replication, targeting cancer tissue while limiting damage to surrounding healthy tissue.